As immediate past-Chair of Diabetes TrialNet, current Director of the TrialNet HUB, and co-PI with Dr. Sandra Lord of TrialNet’s Pacific NW Clinical Center, we are deeply engaged in TrialNet studies and science, including our ongoing Pathway to Prevention trial that screens family member of T1D patients for T1D risk and the successful Teplizumab Prevention Trial.
Learn more about recent and ongoing TrialNet clinical trials in those at-risk of T1D.
- Pathway to Prevention: Ongoing. Screening family members for T1D risk with follow-on monitoring
- Teplizumab Prevention Trial: Completed randomized clinical trial of at-risk individuals resulted in median 2 year delay in development of clinical T1D and led to FDA approval for prevention of disease (REF).
- ATG Prevention Trial: Ongoing randomized clinical trial of at-risk individuals based on significant preservation on insulin secretion (C-peptide) in TN’s ATG trial in recently diagnosed individuals (REF).
- Hydroxychloroquine Prevention Trial: Completed randomized clinical trials of at risk individuals.
- Abatacept Prevention Trial: Completed randomized clinical trial of at risk individuals (Russel et al, 2023 Diabetes Care) based on significant preservation on insulin secretion (C-peptide) in TN’s Abatacept trial in recently diagnosed individuals (Orban, Lancet).
- Oral Insulin Prevention Trial: Completed randomized clinical trial of at-risk individuals. Subgroup with significant delay in T1D progression.
